Mikhail (Misha) Blagosklonny, M.D., Ph.D. graduated with his Doctor of Medicine and Doctorate from First Pavlov State Medical University in St. Petersburg, Russia. He then moved to the United States, where he became well-known for his contributions in cancer and aging research.
Dr. Blagosklonny has published dozens of experimental and theoretical papers focusing on: 1) the hyperfunction theory of aging and, 2) the selective killing of cancer cells with deregulated cell cycle or drug resistance by exploiting their resistance. The hyperfunction theory has led to the rediscovery of Rapamycin as a well-tolerated anti-aging drug. To learn more about this venture, visit Rapamycin Press.
Dr. Blagosklonny is also a founder and Editor-in-Chief at Aging and Oncotarget, an Editor-in-Chief at Oncoscience, and an editor at Genes and Cancer. These four journals are part of the Impact Journals family of scientific publications, based out of Orchard Park, NY.
The editorial board assembled at these acclaimed journals includes some of the most focused and diligent researchers in the world of science and medicine. Many are faculty from Ivy League academic universities and senior staff at renowned clinical institutions. Multiple editorial board members at Impact Journals have been honored by elite scientific societies, such as the United States’ National Academy of Sciences, and have won prestigious awards, including the Breakthrough Prize, the Lasker, and the Nobel Prize.
Dr. Blagosklonny is another beacon of excellence serving on the Impact Journals editorial boards.
Visit Oncotarget.net to hear directly from the distinguished network of authors who continue to publish their research with Oncotarget. Readers may also find information about community events sponsored by Oncotarget.
For those interested in learning more about Oncotarget or in contacting the Journal, visit Oncotarget.com.
For media inquiries, please contact email@example.com.